Biomea Fusion shares rise 10.44% intraday after presenting COVALENT-111 study results showing icovamenib's sustained glucose and C-peptide improvements in type 2 diabetes with good tolerability.
ByAinvest
Wednesday, Dec 10, 2025 10:18 am ET1min read
BMEA--
Biomea Fusion surged 10.44% intraday, following the presentation of COVALENT-111 trial results at the WCIRDC conference on December 5, 2025, which demonstrated durable glucose and C-peptide improvements with icovamenib in type 2 diabetes patients, alongside favorable tolerability. The company is a clinical-stage biopharmaceutical firm specializing in oral small molecule therapies for diabetes and obesity treatment.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet